Sequencing of therapy for patients with diffuse large B‐cell lymphoma in the era of novel drugs
Imke E. Karsten,Evgenii Shumilov,Norbert Schmitz,Georg Lenz
DOI: https://doi.org/10.1111/bjh.19860
2024-10-30
British Journal of Haematology
Abstract:For years, therapy of patients with diffuse large B‐cell lymphoma (DLBCL) was based on the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) regimen in first‐line and eligibility for high‐dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) after response to salvage chemoimmunotherapy in relapsed/refractory patients. In recent years, the therapeutic armamentarium for patients with DLBCL has significantly broadened throughout all lines of therapy. Here, we discuss therapeutic options including the sequencing of novel agents in patients with newly diagnosed and relapsed/refractory DLBCL. Summary Diffuse large B‐cell lymphoma (DLBCL) is the most common aggressive lymphoma, accounting for ~40% of all cases in adults. Whilst approximately two‐thirds of DLBCL patients can be cured by first‐line therapy, one‐third of patients are primary refractory or relapse after an initial response (r/r DLBCL). Recent advances in the treatment of DLBCL have been achieved by a plethora of novel drugs, such as monoclonal antibodies, antibody–drug conjugates (ADC), bi‐specific T‐cell engagers (BITEs), and CD‐19 directed chimeric antigen receptor (CAR)‐T‐cell therapies. The increasing number of therapeutic options significantly improved the outcome of patients; however, the therapeutic algorithm has become increasingly complex. In this review, we provide an overview of novel therapies for DLBCL patients and potential treatment sequencing from first to second, third, and later lines.
hematology